We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Insulet (PODD) Gains As Market Dips: What You Should Know
Read MoreHide Full Article
Insulet (PODD - Free Report) closed the most recent trading day at $296.27, moving +1.35% from the previous trading session. This change outpaced the S&P 500's 0.08% loss on the day. At the same time, the Dow lost 0.34%, and the tech-heavy Nasdaq gained 11.55%.
Prior to today's trading, shares of the maker of insulin infusion systems had lost 3.31% over the past month. This has lagged the Medical sector's gain of 0.62% and the S&P 500's loss of 1.03% in that time.
Insulet will be looking to display strength as it nears its next earnings release. On that day, Insulet is projected to report earnings of $0.24 per share, which would represent a year-over-year decline of 42.86%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $330.36 million, up 7.36% from the year-ago period.
Any recent changes to analyst estimates for Insulet should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 1.93% lower. Insulet is currently a Zacks Rank #4 (Sell).
Digging into valuation, Insulet currently has a Forward P/E ratio of 287.35. Its industry sports an average Forward P/E of 22.78, so we one might conclude that Insulet is trading at a premium comparatively.
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 161, putting it in the bottom 37% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Insulet (PODD) Gains As Market Dips: What You Should Know
Insulet (PODD - Free Report) closed the most recent trading day at $296.27, moving +1.35% from the previous trading session. This change outpaced the S&P 500's 0.08% loss on the day. At the same time, the Dow lost 0.34%, and the tech-heavy Nasdaq gained 11.55%.
Prior to today's trading, shares of the maker of insulin infusion systems had lost 3.31% over the past month. This has lagged the Medical sector's gain of 0.62% and the S&P 500's loss of 1.03% in that time.
Insulet will be looking to display strength as it nears its next earnings release. On that day, Insulet is projected to report earnings of $0.24 per share, which would represent a year-over-year decline of 42.86%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $330.36 million, up 7.36% from the year-ago period.
Any recent changes to analyst estimates for Insulet should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 1.93% lower. Insulet is currently a Zacks Rank #4 (Sell).
Digging into valuation, Insulet currently has a Forward P/E ratio of 287.35. Its industry sports an average Forward P/E of 22.78, so we one might conclude that Insulet is trading at a premium comparatively.
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 161, putting it in the bottom 37% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.